Research programme: inner ear disorder therapeutics - Sensorion

Drug Profile

Research programme: inner ear disorder therapeutics - Sensorion

Alternative Names: SENS-200; SENS-300

Latest Information Update: 25 Aug 2015

Price : $50

At a glance

  • Originator Sensorion
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ear disorders

Most Recent Events

  • 30 Mar 2015 Sensorion has patent protection for SENS 300
  • 21 Jan 2015 Preclinical trials in Ear disorders in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top